SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Sea Otter who wrote (507)3/24/1999 12:58:00 PM
From: 5,17,37,5,101,...  Respond to of 2515
 
Anyone take note of PGNS decline yesterday. Interesting that PGNS, a one drug (cancer-antiangiogenesis approved 1/98 orphan drug status for cyst. fibr. but with a multitude of other possible applications) company, was priced above $50/sh. Now that sales aren't increasing dramatically, PGNS stock is at $11. How does this relate to IMCL. Well, I think C225 will be more effective at what it does with more applications and bigger markets. And there is no generic version available as with Thrombmycin!!! Imagine what final C225 approval will do to IMCL stock price. $50.00? Lowball. I still wonder how it's trading at $14.

Jackson



To: Sea Otter who wrote (507)3/25/1999 10:24:00 AM
From: Raven McCloud  Read Replies (1) | Respond to of 2515
 
Hey Sea Otter,

Looks like once again this morning we're
seeing how strong or weak that $14 floor
is.

Where are you thinking of buying back in?
Think IMCL will break thru $13 once $14 is
solidly taken out?

Thanks for the mkt. analysis; quite interesting.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News